Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin

Overview

cited authors

Boeder, Schafer; Davies, Michael J.; Mcgill, Janet B.; Pratley, Richard; Girard, Manon; Banks, Phillip; Pettus, Jeremy; Garg, Satish

authors

Pratley, Richard Edwin, MD

Publication Date

May 13, 2024

webpage

Web of Science

published in

DIABETES TECHNOLOGY & THERAPEUTICS Journal

Research

keywords

Beta-hydroxybutyrate
Diabetic ketoacidosis
SGLT-2/SGLT-1 inhibitors
Sotagliflozin
Type 1 diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.